MannKind (MNKD) has wrapped up FY 2025 with fourth quarter revenue of US$112 million and a basic EPS loss of US$0.05, setting a clear focal point for investors watching how its income statement is evolving. Over recent periods the company has seen revenue move from US$70 million in Q3 2024 to US$82 million in Q3 2025, while quarterly EPS has ranged from US$0.04 in Q1 2025 to a small profit of US$0.03 in Q3 2025 before this latest loss. This puts the spotlight firmly on how durable its margins really are.

See our full analysis for MannKind.

With the headline numbers on the table, the next step is to line these results up against the widely followed growth and risk narratives around MannKind to see which story, margins under pressure or improving earnings power, appears more consistent with the current data.

Margins Squeezed After TTM Net Margin Slips To 1.7%

• Over the last 12 months, MannKind generated US$348.97 million in revenue and US$5.86 million in net income, which works out to a 1.7% net margin compared with 9.7% a year earlier, and that period also included a one off loss of US$6.4 million.
• Critics highlight that thinner margins limit room for error, and the bearish narrative leans on this. Even so, the trailing 12 month Basic EPS of US$0.02 still sits above the single quarter loss in Q4 2025 and
  • TTM net income of US$5.86 million contrasts with the Q4 2025 net loss of US$15.95 million, so the latest quarter is weaker than the broader 12 month picture that bears focus on.
  • Bears also point to rising costs and pricing pressure, and the drop from a 9.7% margin to 1.7% is consistent with that concern, especially when combined with the one off US$6.4 million loss in the period.

Revenue Near US$349 Million, But Financial Structure Still Fragile

• On a trailing 12 month basis, revenue has reached about US$349.0 million, while interest payments are not well covered by earnings and shareholders' equity is reported as negative, flagging balance sheet risk alongside the income statement progress.
• Bears argue that a weak financial position can overshadow growth, and the cautious narrative leans heavily on this tension between scale and capital structure
  • Even with TTM net income of US$5.86 million, analysts note that interest coverage remains poor, which supports the bearish concern that earnings do not yet comfortably support financing costs.
  • Negative equity means liabilities exceed accounting equity, fitting the bearish view that MannKind may need to lean on external funding if spending stays high relative to profitability.

Line up this mixed margin picture with what skeptics are saying about MannKind's dependence on a few key products and funding needs by checking the detailed bear case: 🐻 MannKind Bear Case

TTM EPS Positive As Growth Expectations Stay High

• Despite the Q4 2025 Basic EPS loss of US$0.05, trailing 12 month Basic EPS is still US$0.02, and analysts are forecasting earnings growth of about 32.2% per year and revenue growth of about 12% per year from this base.
• Supporters argue this mix of positive TTM earnings and higher forecast growth rates backs a bullish view, and the optimistic narrative leans on that, even though current valuation signals are mixed.
  • At a share price of US$3.28, the stock sits below a DCF fair value of about US$4.51 and trades on a P/S of 2.9x compared with 12.6x for the US Biotechs industry and 6.5x for peers, which bullish investors see as a discount.
  • At the same time, analysts' price targets are capped at US$8.50 in this framework, so bulls are effectively arguing that the gap between current price and both growth forecasts and this target leaves room for upside if earnings track expectations.

If you want to see how supporters of the growth story connect these margin and valuation numbers, take a look at the full bull case for MannKind here: 🐂 MannKind Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for MannKind on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages from the data so far? If you want to move quickly and firm up your own view, it is worth weighing both the upside and the concerns by checking 4 key rewards and 5 important warning signs.

See What Else Is Out There

MannKind's thin 1.7% TTM net margin, Q4 loss, poor interest coverage, and negative equity all point to a capital structure that leaves little room for setbacks.

If that balance sheet fragility makes you uneasy, consider putting your capital to work in companies screened for stronger financial footing by checking solid balance sheet and fundamentals stocks screener (39 results) today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.